News
MyChesCo on MSN16h
Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis
SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback